Rep. Lisa C. McClain Sells Amgen Inc. (NASDAQ:AMGN) Stock

Representative Lisa C. McClain (R-Michigan) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on September 25th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of FMC (NYSE:FMC) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Merit Medical Systems (NASDAQ:MMSI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Darden Restaurants (NYSE:DRI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of Beacon Financial (NYSE:BBT) on 9/25/2025.
• Sold $1,001 – $15,000 in shares of British American Tobacco (NYSE:BTI) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of Rollins (NYSE:ROL) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 9/25/2025.
• Purchased $1,001 – $15,000 in shares of MGP Ingredients (NASDAQ:MGPI) on 9/25/2025.

Amgen Stock Down 0.4%

Shares of NASDAQ AMGN opened at $291.76 on Friday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $157.07 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.53 and a beta of 0.49. The stock has a 50 day moving average price of $287.92 and a 200 day moving average price of $287.31. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a $2.38 dividend. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. Amgen’s payout ratio is presently 77.84%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.76% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amgen

A number of large investors have recently made changes to their positions in the business. Wealth Preservation Advisors LLC acquired a new position in shares of Amgen in the 1st quarter valued at $25,000. First Pacific Financial increased its position in shares of Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67 shares during the period. CBIZ Investment Advisory Services LLC increased its position in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares during the period. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 2nd quarter valued at $27,000. Finally, Activest Wealth Management increased its position in shares of Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 103 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of analyst reports. Citigroup upped their target price on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Weiss Ratings restated a “buy (b-)” rating on shares of Amgen in a report on Friday. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Sunday, October 19th. Piper Sandler upped their target price on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Finally, Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They set a “market perform” rating for the company. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average target price of $300.94.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.